{
      "Rank": 227,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg",
            "Aspirin Tablet, 100mg/d; Placebo"
      ],
      "ArmGroupInterventionName": [
            "Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
            "Drug: Aspirin Tablet",
            "Drug: Aspirin Tablet"
      ],
      "ArmGroupLabel": [
            "Group 1",
            "Group 2"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03186456"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC)."
      ],
      "BriefTitle": [
            "The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife\u00ae-ACI) in the Treatment of Acute Cerebral Infarction"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Cerebral Infarction"
      ],
      "ConditionAncestorId": [
            "D000007511",
            "D000010335",
            "D000009336",
            "D000020520",
            "D000002545",
            "D000002561",
            "D000001927",
            "D000002493",
            "D000009422",
            "D000020521",
            "D000014652",
            "D000002318"
      ],
      "ConditionAncestorTerm": [
            "Ischemia",
            "Pathologic Processes",
            "Necrosis",
            "Brain Infarction",
            "Brain Ischemia",
            "Cerebrovascular Disorders",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Stroke",
            "Vascular Diseases",
            "Cardiovascular Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC10",
            "BC14",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Nervous System Diseases",
            "Heart and Blood Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Infarction",
            "Cerebral Infarction"
      ],
      "ConditionBrowseLeafId": [
            "M9434",
            "M4945",
            "M9695",
            "M11436",
            "M21458",
            "M4946",
            "M4962",
            "M4356",
            "M4894",
            "M21459",
            "M16552",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Infarction",
            "Cerebral Infarction",
            "Ischemia",
            "Necrosis",
            "Brain Infarction",
            "Brain Ischemia",
            "Cerebrovascular Disorders",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Stroke",
            "Vascular Diseases",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000002544",
            "D000007238"
      ],
      "ConditionMeshTerm": [
            "Cerebral Infarction",
            "Infarction"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Double"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Investigator"
      ],
      "DetailedDescription": [
            "This is a randomized, double-blind, paralleled study. 40 patients will be separated into two groups, and receive basic treatment (Aspirin Tablet). Patients in experimental group will receive hUC-MSC once a month, total 3 times. After the treatment, investigator will have follow-up visit for 6 months, evaluate the security and efficacy of hUC-MSC."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatient within 2 weeks onset of symptoms.\nSymptoms and signs of clinically definite acute cerebral infarction patients.\nCT/MRI prove the Oxfordshire Community Stroke Project (OCSP) as Total Anterior circulation infarct (TACI), Partial Anterior circulation infarct (PACI), Posterior Anterior circulation infarct (POCI), or obvious neurological deficit lacunar infarction patient.\nSigned informed consent after understanding all possible benefits and harm.\n\nExclusion Criteria:\n\nallergic to basic drug\nwith progressive stroke, transient ischemia attach, cerebral infarction with posterior cerebral hemorrhage, and cerebral arteritis.\ntumor, injury, and parasites caused cerebral embolism\nrheumatic heart disease, coronary heart disease, and other atrial fibrillation combined heart disease caused cerebral embolism\nsubject is processing thrombolytic therapy\nsubject is pregnancy and of childbearing potential or breast feeding\nparticipate in any other clinical trial in last 3 months\nbleeding tendency patient; severe bleeding tendency in last 3 month\nwith gastric duodenal ulcer\nparticipants with severe liver and kidney, hematopoietic, and metabolic diseases; Or with liver and kidney function examination abnormal\nparticipants are intolerance with Aspirin Enteric-coated Tablets, or need other antiplatelet drugs\nparticipants: alcoholism, drug addicted, or other situations may complicated the results\nunder other therapy that possibly influence MSC security or efficacy\ninvestigator supposes not suitable to participate this clinical trail"
      ],
      "EnrollmentCount": [
            "40"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000894",
            "D000018712",
            "D000000700",
            "D000018689",
            "D000018373",
            "D000045505",
            "D000000893",
            "D000018501",
            "D000005343",
            "D000050299",
            "D000045504",
            "D000010975",
            "D000016861",
            "D000004791",
            "D000058633"
      ],
      "InterventionAncestorTerm": [
            "Anti-Inflammatory Agents, Non-Steroidal",
            "Analgesics, Non-Narcotic",
            "Analgesics",
            "Sensory System Agents",
            "Peripheral Nervous System Agents",
            "Physiological Effects of Drugs",
            "Anti-Inflammatory Agents",
            "Antirheumatic Agents",
            "Fibrinolytic Agents",
            "Fibrin Modulating Agents",
            "Molecular Mechanisms of Pharmacological Action",
            "Platelet Aggregation Inhibitors",
            "Cyclooxygenase Inhibitors",
            "Enzyme Inhibitors",
            "Antipyretics"
      ],
      "InterventionArmGroupLabel": [
            "Group 1",
            "Group 1",
            "Group 2"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Antipy",
            "Infl",
            "ARhu",
            "FiAg",
            "Analg",
            "PlAggInh",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Antipyretics",
            "Anti-Inflammatory Agents",
            "Antirheumatic Agents",
            "Fibrinolytic Agents",
            "Analgesics",
            "Platelet Aggregation Inhibitors",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Dietary Supplement"
      ],
      "InterventionBrowseLeafId": [
            "M3700",
            "M3369",
            "M3370",
            "M3184",
            "M19939",
            "M19757",
            "M7625",
            "M13017",
            "M18361",
            "M28329"
      ],
      "InterventionBrowseLeafName": [
            "Aspirin",
            "Anti-Inflammatory Agents",
            "Anti-Inflammatory Agents, Non-Steroidal",
            "Analgesics",
            "Analgesics, Non-Narcotic",
            "Antirheumatic Agents",
            "Fibrinolytic Agents",
            "Platelet Aggregation Inhibitors",
            "Cyclooxygenase Inhibitors",
            "Antipyretics"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 *10^6/kg. once a month, total 3 times.",
            "Drug: Aspirin Tablet, 100 mg/d"
      ],
      "InterventionMeshId": [
            "D000001241"
      ],
      "InterventionMeshTerm": [
            "Aspirin"
      ],
      "InterventionName": [
            "Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
            "Aspirin Tablet"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [
            "No"
      ],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "acute cerebral infarction",
            "umbilical cord mesenchymal stem cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "May 9, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "May 5, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Sclnow Biotechnology Co., Ltd."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Hohhot"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "Inner Mongolia International Mongolian Hospital"
      ],
      "LocationState": [
            "Inner Mongolia"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "010065"
      ],
      "MaximumAge": [
            "75 Years"
      ],
      "MinimumAge": [
            "40 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Sclnow Biotechnology Co., Ltd."
      ],
      "OrgStudyId": [
            "SCLnow-IMIMH-02"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Inner Mongolia International Mongolian Hospital",
            "China-Japan Union Hospital, Jilin University"
      ],
      "OverallOfficialName": [
            "Temuqile",
            "Lei Guo, Dr."
      ],
      "OverallOfficialRole": [
            "Study Director",
            "Study Chair"
      ],
      "OverallStatus": [
            "Suspended"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "patients will be monitored for any adverse events resulting from the treatment of Human Umbilical Cord Mesenchymal Stem Cells"
      ],
      "PrimaryOutcomeMeasure": [
            "Treatment related-adverse events counting"
      ],
      "PrimaryOutcomeTimeFrame": [
            "26 weeks"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "After the first time transplantation, follow-up visit for 26 weeks. Based on Modified Rankin Scale, counting the percentage of different symptom changes to evaluate MSC efficacy:\n\nthe percentage of participants run from 0-1, no symptom or no significant disability.\nthe percentage of participants run from 0-2, no symptom or slight disability.\nthe percentage of participants decline 2 scales compare to baseline.\nthe percentage of participants decline 1 scale compares to baseline.",
            "Based on Activity of Daily Living Scale (ADL) to counting the percentage of patients in following condition:\n\nthe percentage of patients with score > 75\nthe decline of Barthel ADL Index range compares to baseline. Evaluate the efficacy of MSCs treatment",
            "According to NIHSS changes after the treatment, evaluate MSCs efficacy by counting the percentage of patients in following condition:\n\nthe percentage of patients with score 0-1;\nthe percentage of patients with score declined 7 compare to baseline;\nthe percentage of patients with score declined 50% compare to baseline;\nthe declined ranges compare to baseline"
      ],
      "SecondaryOutcomeMeasure": [
            "Modified Rankin Scale",
            "Barthel activities of daily living (ADL) Index",
            "NIH stroke scale (NIHSS)"
      ],
      "SecondaryOutcomeTimeFrame": [
            "26 weeks",
            "26 weeks",
            "26 weeks"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "June 2022"
      ],
      "StartDateType": [
            "Anticipated"
      ],
      "StatusVerifiedDate": [
            "January 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 14, 2017"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "June 6, 2017"
      ],
      "StudyFirstSubmitQCDate": [
            "June 12, 2017"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": [
            "Others"
      ]
}